Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease
Targeting glucose control and managing cardiovascular (CV) risk factors may prevent future CV events, and have positive downstream impact by reducing costs to healthcare stakeholders.
Metastatic Non–Small Cell Lung Cancer: Costs Associated With Disease Progression
The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
